All In Biotech

BLA 125277 · Dyax Corp.

Kalbitor

Ecallantide · Injection · Plasma Kallikrein Inhibitor

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Dec 28, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Dec 1, 2009

Approved uses

2

Original approval plus efficacy supplements

Registered trials

12

4 Phase 3, 0 recruiting

FAERS reports

1,869

1,138 serious, 34 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ANAPHYLAXIS Anaphylaxis has been reported after administration of KALBITOR. Because of the risk of anaphylaxis, KALBITOR should only be administered by a healthcare professional with appropriate medical support to manage anaphylaxis and hereditary angioedema. Healthcare professionals should be aware of the similarity of symptoms between hypersensitivity reactions and hereditary angioedema and patients should be monitored closely. Do not administer KALBITOR to patients with known clinical hypersensitivity to KALBITOR. [ see Contraindications (4) , Warnings and Precautions (5.1) , and Adverse Reactions (6) ] WARNING: ANAPHYLAXIS See full prescribing information for complete boxed warning Anaphylaxis has been reported after administration of KALBITOR ® . Because of the risk of anaphylaxis, KALBITOR should only be administered by a healthcare professional with appropriate medical...

What it is approved for

From the label in effect Jul 1, 2025.

KALBITOR ® (ecallantide) is indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older. KALBITOR is a plasma kallikrein inhibitor indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older. ( 1 )

Mechanism: Hereditary angioedema (HAE) is a rare genetic disorder caused by mutations to C1-esterase-inhibitor (C1-INH) located on Chromosome 11q and inherited as an autosomal dominant trait. HAE is characterized by low levels of C1-INH activity and low levels of C4. C1-INH functions to regulate the activation of the complement and intrinsic coagulation (contact system pathway) and is a major endogenous inhibitor of plasma kallikrein. The kallikrein-kinin system is a complex proteolytic cascade involved in the initiation of both inflammatory and coagulation pathways. One critical aspect of this pathway...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 28, 2014 Supplement 70 · Efficacy · priority review LetterLabel
  • Dec 1, 2009 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewSummary Review
1 products under this application
  • KALBITOR · ECALLANTIDE 10MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ecallantide" as an intervention, any sponsor and status, largest first.

All 12 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hereditary angioedema782
  • off label use170
  • drug ineffective147
  • malaise86
  • headache84
  • product dose omission issue72
  • pain70
  • hypersensitivity68
  • weight decreased68
  • nausea67
  • anaphylactic reaction62
  • weight increased60

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20109
201120
201267
201370
2014197
2015333
2016499
201769
2018124
201986
202084
202178
202262
202338
202438
202564
202631

Recalls

1 FDA enforcement reports for this application.

  • Mar 17, 2017 · Class II · Terminated

    Presence of Particulate Matter: Glass

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Kalbitor (Ecallantide)

2024 spending

$20.9M

Beneficiaries

36

284 claims

Per beneficiary

$579,766

$5,624.25 per unit

View as table
YearSpending
2020$15,473,075
2021$20,767,296
2022$26,210,230
2023$24,976,935
2024$20,871,584

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 18 on PubMed

Sponsor: Dyax Corp.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.